
COVID-19 Surveillance Seminar- May 29, 2020

Surveillance Strategies for COVID-19 Human Infection

Anne Perrocheau, Technical Lead for Surveillance Incident Management Support Team for COVID-19 response World Health Organization

Veronica Pinell-McNamara, Epidemiologist
Division of Bacterial Diseases
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention





For more information: www.cdc.gov/COVID19

SURVEILLANCE STRATEGIES FOR GOWILLMAN INFECTION

Dr. Anne Perrocheau Technical lead for Surveillance Incident Management Support Team for COVID-19 response World Emergency Program Geneva



Surveillance of COVID-19 human infection: national surveillance

- Objectives of national surveillance:
 - enable rapid detection, isolation, testing, and management of suspected cases
 - identify and follow up contacts
 - guide the implementation of control measures
 - detect and contain outbreaks among vulnerable populations
 - evaluate the impact of the pandemic on health-care systems and society
 - monitor longer term epidemiologic trends and evolution of COVID-19 virus
 - understand the co-circulation of COVID-19 virus, influenza and other respiratory viruses

WHO recommended strategies for national Surveillance

1. Strengthen existing surveillance capacities

- adapt existing surveillance systems
- COVID-19 as a mandatory notifiable disease
- immediate reporting

2. Scale-up of additional surveillance capacities as needed

- in community: EWAR system, community surveillance, event based surveillance, participatory surveillance
- in vulnerable groups: EWAR, active case finding, daily clinical check, zero reporting

3. Use **innovative** technologies for surveillance

- digital/electronic technologies for rapid reporting, data management, and analysis
- Apps for contact tracing, hotlines, self reporting platform

Type of surveillance and surveillance sites for COVID-19

			Surveillance !	Sites		
Type of Surveillance	Individuals in the Community	Primary Care Sites	Hospital	Sentinel ILI/SARI Site	Residential Facilities and Vulnerable Groups	Vital Statistics Offices
Immediate Case notification system	X	Х	X	X	X	
Contact tracing system	Х					
Sentinel virus surveillance			Х	Х		
Sentinel case surveillance		(X)	Х	Х		
Cluster investigations	Х	Х	Х	Х	Х	
Special settings surveillance			X		X	
Mortality surveillance	X		X	X	X	Χ

Surveillance sites - 1

- Community
 - Community and event based surveillance
 - Contract tracing, cluster investigation
 - Participatory surveillance, telephones hotlines, self reporting platform
- Primary care level
 - Probable and confirmed cases
 - 24 h notification
 - Zero reporting
 - Limited set of data (age, sex, date onset, date sample, test result, location testing site)

Surveillance sites - 2

- Hospital
 - Probable and confirmed cases
 - Minimum data set: age, sex/gender and place of residence, date of onset, date of sample collection, date of admission, laboratory test result, severity on admission: admitted to intensive care unit (ICU), treated with ventilation, health care worker status, outcome (discharge or death) if follow-up report feasible.
- Global Influenza Surveillance and Response System
 - For ILI and SARI
 - Community transmission
 - Virological surveillance and Sequencing

Surveillance sites - 3

- Vulnerable groups: residential facilities, closed settings
 - Active case finding, daily screening
 - zero reporting
 - Health care workers: clusters investigation, specific study
- Humanitarian settings
 - EWAR, community surveillance
 - Active case findings
 - Identification of high risk individuals
- Mortality surveillance
 - Case based surveillance daily, weekly reporting
 - Religious centers, burial sites
 - Vital statistics

THANK YOU FOR YOUR ATTENTION



Overview of Surveillance Strategies for COVID-19 Outlined in WHO Guidance

Operationalizing guidance to review objectives and indicators by surveillance strategies

Veronica Pinell-McNamara

Epidemiologist

Division of Bacterial Diseases

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention



Outline

- Objectives of the surveillance
- Short- and long-term goals
 - Review indicators from each
- Surveillance systems
 - How systems can meet those objectives
 - Indicators each can get from each
- Considerations for incorporating COVID-19



Short-Term Objectives

- Characterize the outbreak to guide control measures and limit spread of disease
 - Enable rapid detection, isolation, testing and management of suspected cases
 - Identify and follow up contacts
 - Detect and contain outbreaks among vulnerable populations
 - Guide the implementation of control measures



Short-Term Indicators

Weekly reporting to WHO by age and sex:

- # new confirmed cases
- # deaths in confirmed cases (case fatality rate)
- # new confirmed cases hospitalized (general and intensive care unit [ICU], if available)
- # confirmed cases discharged or recovered
- # persons tested for COVID-19



Long-Term Objectives

- Monitor longer term epidemiologic trends and evolution of COVID-19 virus
- Evaluate the impact of the pandemic on health-care systems and society
- Understand the co-circulation of COVID-19 virus, influenza, and other respiratory viruses



- Overall and weekly regional trends (by age, sex, race)
 - # confirmed COVID-19 cases by subnational levels
 - Incidence rates (general and by subnational levels)
 - % SARS-CoV-2 cases out of hospitalized severe acute respiratory infection (SARI)
 - % SARS-CoV-2 cases out of outpatient influenza-like illness (ILI) cases



- Changes in deaths (by region, age, sex, and race)
 - # deaths in confirmed cases (case fatality rate)
 - # confirmed COVID-19 deaths among hospitalized (hCFR (%))
 - # deaths of COVID-like illness (pneumonia, ILI/SARI and other, including country or geography specific conditions)
 - Estimate of excess all cause mortality (the degree to which currently measured mortality exceeds historically established level)



- Changes in risk factors or co-morbidities (by region, age, sex)
 - % cases with risk factors (by underlying conditions or co-morbidity)
 - % deaths with risk factors (by underlying conditions or co-morbidity)



Indicators to Evaluate the Impact of the Pandemic on Healthcare Systems and Society

- Core indicators (by age/sex-reported daily/weekly and cumulatively)
 - # new confirmed cases hospitalized (general and ICU, if available)
 - # confirmed cases discharged or recovered
 - % hospital or ICU beds occupied
 - % hospitalized confirmed COVID-19 cases out of all hospitalizations
 - # confirmed cases among HCW
 - # confirmed case deaths among HCW
 - Estimate of excess mortality



Indicators to Understand the Co-circulation of COVID-19 Virus, Influenza and Other Respiratory Viruses

- Trends over time (by age, sex, region)
 - % positive specimens for SARS-CoV-2 vs. other respiratory viruses



Objectives of Systems

System	Objective
National surveillance (aggregate or case-based)	Identify all cases of disease at all levels of health system for any nationally notifiable disease to characterize trends and risk factors associate with disease.
Sentinel surveillance	Identify all cases of disease in a specific site with strong laboratory confirmation to characterize trends and risk factors associated with disease.
Mortality surveillance	Identify deaths attributable to disease and estimate case fatality proportion and risk factors associated with mortality.



Indicators to Characterize Outbreak by Surveillance System

Core indicators (by age/sex – reported daily/weekly and cumulatively)	Universal surveillance	Sentinel surveillance	Mortality surveillance
# new confirmed cases			
# deaths in confirmed cases (case-fatality rate)	*		
# new confirmed cases hospitalized (general and ICU, if available)			
# confirmed cases discharged or recovered			
# persons tested for COVID-19			

^{*}Mortality information is difficult to access from universal surveillance systems unless the event occurs at the time of reporting and often is not updated after reporting unless system is structured to specifically obtain this information.



Core indicators (by age/sex – reported daily/weekly and cumulatively)	National surveillance	Sentinel surveillance	Mortality surveillance
# confirmed COVID-19 cases by subnational levels			
Incidence rates (general and by subnational levels)			
% SARS-CoV-2 cases out of SARI (hospitalized)			
% SARS-CoV-2 cases out of ILI cases (outpatient)			



Core indicators (by age/sex – reported daily/weekly and cumulatively)	National surveillance	Sentinel surveillance	Mortality surveillance
# deaths in confirmed cases (case-fatality rate)	*		
# confirmed COVID-19 deaths among hospitalized cases (hCFR (%))			
# deaths of COVID-like illness (pneumonia, ILI/SARI and other, including country/ geography specific conditions)			
Estimate of excess all-cause mortality (the degree to which currently measured mortality exceeds historically established level)			

^{*}Mortality information is difficult to access from universal surveillance systems unless the event occurs at the time of reporting and often is not updated after reporting unless system is structured to specifically obtain this information.



Aggregate only	Aggregate and case-based reporting
Case based reporting only	Population based

Overall and weekly (by age, sex)	National surveillance	Sentinel surveillance	Mortality surveillance
% confirmed cases with risk factors (by underlying conditions or co-morbidity)			
% confirmed deaths with risk factors (by underlying conditions or co-morbidity)			



Indicators to Evaluate the Impact of the Pandemic on Healthcare Systems and Society

Core indicators (by age/sex - reported	Universal	Sentinel	Mortality
daily/weekly and cumulatively)	surveillance	surveillance	surveillance
# new confirmed cases hospitalized			
(general and ICU, if available)			
# confirmed cases discharged or recovered			
% hospital or ICU bed occupied			
% hospitalized confirmed COVID-19 cases out			
of all hospitalizations			
# confirmed cases among HCW			
# confirmed case deaths among HCW	*		
Estimate of excess all-cause mortality			

^{*}Mortality information is difficult to access from universal surveillance systems unless the event occurs at the time of reporting and often is not updated after reporting unless system is structured to specifically obtain this information.



Aggregate only	Aggregate and case-based reporting
Case based reporting only	Population based

Indicators to Understand the Co-circulation of COVID-19 Virus, Influenza, and Other Respiratory Viruses

Core indicators (by age/sex – reported daily/weekly and cumulatively)	National surveillance	Sentinel surveillance	Mortality surveillance
% positive specimens for SARS-CoV-2 vs. other respiratory viruses			



Strengths

National surveillance	Sentinel surveillance	Mortality surveillance
Can provide estimates on burden of disease across regions and nationally Can generate incidence rates for easy interpretation of data	Trained personnel to implement syndromic surveillance Detailed case information (mild-severe disease) Requires limited resources	Can monitor outcome, disparities in disease across geographic and demographic groups



Limitations

National surveillance	Sentinel surveillance	Mortality surveillance
Identification of trends dependent on completeness of variables collected and reliability of lab results	May not be population- based or geographically representative	Weekly counts are rarely published from low-middle-income countries
Need extensive clinical and lab capacity and resources for robust data management		May require indirect demographic methods for baseline measures or advanced estimation methods for population structure



Considerations for Incorporating COVID-19 Surveillance



Adapt and strengthen existing surveillance systems

At different levels of health care system



Mandatory reporting



Immediate reporting where feasible



Digital technologies

Rapid reporting for data management where possible



Laboratory capacity

SARSCoV-2-positive and total tests conducted



Representativeness

Geographically, age, risk factors of broader population



Survey of Country Offices

9 responses

- Africa Region (n=7)
- Latin America (n=1)
- Asia (n=1)

System	Q2 What surveillance systems are you considering COVID-19?	Q3 What system do you want guidance for?
Acute febrile illness	44%	33%
Mortality surveillance	33%	56%
Case-based surveillance	56%	33%
ILI surveillance	67%	56%
SARI surveillance	78%	56%
Aggregate surveillance	33%	22%
Community event-based surveillance	56%	56%
Malaria surveillance	33%	22%
Polio surveillance	22%	33%



Upcoming Webinars

- Please join us next week, same place, same time for a session on electronic tools to support surveillance.
- Following webinars to come, including mortality surveillance, syndromic surveillance, serosurveys, and more!



WHO Resources for COVID-19 Surveillance

- Surveillance strategies for COVID-19 human infection (https://www.who.int/publications-detail/surveillance-strategies-for-covid-19-human-infection, assessed 10 May 2020)
- Contact tracing in context of COVID-19 (https://www.who.int/publications-detail/contact-tracing-in-the-context-of-covid-19, assessed 10 May 2020)
- Global surveillance for COVID-19 caused by human infection with COVID-19 virus (<a href="https://www.who.int/publications-detail/global-surveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-interim-guidance, assessed 20 April 2020, assessed 20 April 2020)
- Case based reporting form (https://www.who.int/publications-detail/case-based-reporting-form, accessed 28 February 2020)
- Global surveillance of COVID-19: WHO process for reporting aggregated data (https://www.who.int/publications-detail/aggregated-weekly-reporting-form, assessed 6 April 2020)
- Considerations in the investigation of cases and clusters of COVID-19 (Interim Guidance) (https://www.who.int/publications-detail/considerations-in-the-investigation-of-cases-and-clusters-of-covid-19, accessed 02 April 2020)
- Operational considerations for COVID-19 surveillance using GISRS (https://www.who.int/publications-detail/operational-considerations-for-covid-19-surveillance-using-gisrs-interim-guidance, assessed 26 March 2020)
- Laboratory testing strategy recommendations for COVID-19 (Interim Guidance) (https://www.who.int/publications-detail/critical-preparedness-readiness-and-response-actions-for-covid-19, accessed 22 March 2020)
- Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-19) (Interim Guidance)
 (<a href="https://www.who.int/publications-detail/considerations-for-quarantine-ofindividuals-in-the-context-of-containment-for-coronavirus-disease-(covid-19), accessed 19 March 2020)

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

